Cell-free DNA diagnostics: current and emerging applications in oncology.

abstract：AIM:To determine the availability of pharmacogenetic and pharmacogenomic information for healthcare professionals in France during 2009 for anticancer drugs. MATERIALS & METHODS:We searched in the informatic version of the VIDAL dictionary which is currently used by healthcare professionals in France. We then compared...

journal_title：Pharmacogenomics

authors： Albertini L,Siest G,Jeannesson E,Visvikis-Siest S

更新日期：2011-05-01 00:00:00

abstract：AIM:Gemcitabine is the first chemotherapeutic agent to show clinical benefits in pancreatic cancer patients. While interindividual variability in chemoresponse is observed, genetic factors that affect drug metabolism have not been clearly defined. The purpose of this study is to evaluate the relationships between genet...

journal_title：Pharmacogenomics

authors： Woo HI,Kim KK,Choi H,Kim S,Jang KT,Yi JH,Park YS,Park JO,Lee SY

更新日期：2012-07-01 00:00:00

abstract：:Aim: The CYP2D6 gene is highly polymorphic and harbors population specific alleles that define its predominant metabolizer phenotype. This study aimed to identify polymorphisms in Indian population owing to scarcity of CYP2D6 data in this population. Materials & methods: The CYP2D6 gene was resequenced in 105 south In...

journal_title：Pharmacogenomics

authors： Manoharan A,Shewade DG,Ravindranath PA,Rajkumar RP,Ramprasad VL,Adithan S,Damodaran SE

更新日期：2019-07-01 00:00:00

abstract：AIM:This study aims to evaluate the association between the MTRR rs1801394 alone or in interaction with the MTHFR rs1801133 and susceptibility to colorectal cancer (CRC) and its characteristics in Iranian population. Additionally, both a systematic review and meta-analysis were performed to derive a more precise assess...

journal_title：Pharmacogenomics

authors： Haerian MS,Haerian BS,Molanaei S,Kosari F,Sabeti S,Bidari-Zerehpoosh F,Abdolali E

更新日期：2017-07-01 00:00:00

abstract：AIM:Several HLA alleles have been associated with antiepileptic drugs (AEDs)-induced cutaneous adverse drug reactions (cADRs) in different populations; however, this has not been investigated in Mexican Mestizos (MM). Thus, the purpose of this preliminary study was to determine the association of HLA class I alleles wi...

journal_title：Pharmacogenomics

authors： Fricke-Galindo I,Martínez-Juárez IE,Monroy-Jaramillo N,Jung-Cook H,Falfán-Valencia R,Ortega-Vázquez A,Alonso-Vilatela ME,López-López M

更新日期：2014-01-01 00:00:00

abstract：:Type B adverse drug reactions (ADRs) are often serious, limit the usefulness of drugs that are otherwise effective, and increase the risks of drug development as they often lead to postmarketing withdrawal. There is evidence that susceptibility to at least some Type B ADRs is under strong genetic influence. Identifyin...

journal_title：Pharmacogenomics

authors： Molokhia M,McKeigue P

更新日期：2006-06-01 00:00:00

abstract：:Aim: To define the impact of polymorphisms in genes involved in platinum-taxane and estrogen activity in the outcome of platinum-based treated ovarian cancer patients (OCP). Patients & Methods: Two hundred and thirty OCP were analyzed for 124 germ-line polymorphisms to generate a prognostic score for overall survival ...

journal_title：Pharmacogenomics

authors： Gagno S,Bartoletti M,Romualdi C,Poletto E,Scalone S,Sorio R,Zanchetta M,De Mattia E,Roncato R,Cecchin E,Giorda G,Toffoli G

更新日期：2020-09-01 00:00:00

abstract：:The value of high-throughput genomic research is dramatically enhanced by association with key patient data. These data are generally available but of disparate quality and not typically directly associated. A system that could bring these disparate data sources into a common resource connected with functional genomic...

journal_title：Pharmacogenomics

authors： Thallinger GG,Trajanoski S,Stocker G,Trajanoski Z

更新日期：2002-09-01 00:00:00

abstract：:Chronic fatigue syndrome (CFS) is prevalent, disabling and costly. Despite extensive literature describing the epidemiology and clinical aspects of CFS, it has been recalcitrant to diagnostic biomarker discovery and therapeutic intervention. This is due to the fact that CFS is a complex illness defined by self-reporte...

journal_title：Pharmacogenomics

authors： Vernon SD,Whistler T,Aslakson E,Rajeevan M,Reeves WC

更新日期：2006-03-01 00:00:00

abstract：:While antidepressants are widely used to treat mood and anxiety disorders, only half of the patients will respond to antidepressant treatment and only one-third of patients experience a full remission of symptoms. The identification of genetic biomarkers that predict antidepressant-treatment response can improve curre...

journal_title：Pharmacogenomics

authors： Narasimhan S,Lohoff FW

更新日期：2012-03-01 00:00:00

abstract：AIM:No definite factors predict blood pressure response to angiotensin-converting enzyme-inhibitors. The aim of this study was to test the association of gene polymorphisms of the renin-angiotensin-aldosterone system with essential hypertension and anthropometric variables, intermediate phenotypes and gene polymorphism...

journal_title：Pharmacogenomics

authors： Filigheddu F,Argiolas G,Bulla E,Troffa C,Bulla P,Fadda S,Zaninello R,Degortes S,Frau F,Pitzoi S,Glorioso N

更新日期：2008-10-01 00:00:00

abstract：:Aim: The need for pharmacogenomic education is becoming more and more urgent. Our aim was to evaluate the progress in pharmacogenomics education since then, and to put forward further recommendations. Methods: A survey was sent to 248 schools of medicine, pharmacy, nursing and health professions around the world. Resu...

journal_title：Pharmacogenomics

authors： Karas Kuželički N,Prodan Žitnik I,Gurwitz D,Llerena A,Cascorbi I,Siest S,Simmaco M,Ansari M,Pazzagli M,Di Resta C,Brandslund I,Schwab M,Vermeersch P,Lunshof JE,Dedoussis G,Flordellis CS,Fuhr U,Stingl JC,van Schaik RH

更新日期：2019-06-01 00:00:00

abstract：AIM:This national dissemination study evaluated pharmacy students' self-reported overall ability, self-efficacy and attitudes toward applying pharmacogenomics and perceptions of Pharmacogenomics Education Program, a shared pharmacogenomics curriculum. PATIENTS & METHODS:Following a series of train-the-trainer programs...

journal_title：Pharmacogenomics

authors： Lee KC,Hudmon KS,Ma JD,Kuo GM

更新日期：2015-01-01 00:00:00

abstract：:Comprehensive, systematic and integrated data-centric statistical approaches to disease modeling can provide powerful frameworks for understanding disease etiology. Here, one such computational framework based on redescription mining in both its incarnations, static and dynamic, is discussed. The static framework prov...

journal_title：Pharmacogenomics

authors： Waltman P,Pearlman A,Mishra B

更新日期：2006-04-01 00:00:00

abstract：:Genome-wide association studies (GWAS) allow the finding of genetic variants associated with several traits. Regarding ovarian cancer (OC), 15 GWAS have been conducted since 2009, with the discovery of 49 SNPs associated with disease susceptibility and 46 with impact in the clinical outcome of patients (p < 5.00 × 10-...

journal_title：Pharmacogenomics

authors： Pinto R,Assis J,Nogueira A,Pereira C,Pereira D,Medeiros R

更新日期：2017-11-01 00:00:00

abstract：:Pharmacogenomics studies the influence of genomics on drug response safety and efficacy. Although research in this field was initiated many years ago, few functional applications are currently in use at the clinic. MicroRNAs (miRNAs) are short noncoding RNAs that bind genes and silence their expression. MiRNAs are enc...

journal_title：Pharmacogenomics

authors： Shomron N

更新日期：2010-05-01 00:00:00

abstract：:Assessing the distinct prevalence or absence of genetic variants associated with differential response to the anticoagulant medication of warfarin in different population groups is actively pursued by pharmacogenomics community. Populations from Arabian Peninsula are underrepresented in such studies. By way of examini...

journal_title：Pharmacogenomics

authors： John SE,Antony D,Eaaswarkhanth M,Hebbar P,Alkayal F,Tuomilehto J,Alsmadi O,Thanaraj TA

更新日期：2017-06-01 00:00:00

abstract：:This review will summarize the role of pharmacogenetics in the natural history of hepatitis C, particularly in patients with HIV/HCV and will take the perspective of pharmacogenetics and its influence on the response to antiviral therapy and the susceptibility to develop adverse effects. This review will also devote a...

journal_title：Pharmacogenomics

authors： Frias M,Rivero-Juárez A,López-López P,Rivero A

更新日期：2018-08-01 00:00:00

abstract：:Healthcare professionals (e.g., physicians, physician assistants, pharmacists, nurses and genetic counselors) believe pharmacogenomics (PGx) is essential to personalized medicine; however, they still lack confidence prescribing, dosing, interacting with other healthcare professionals and counseling patients with regar...

journal_title：Pharmacogenomics

authors： Nickola TJ,Green JS,Harralson AF,O'Brien TJ

更新日期：2012-09-01 00:00:00

abstract：:Toxicogenomics is, arguably, the most exciting endeavor to better understand and/or predict the toxicity of drugs during their development, using technologies such as gene-expression microarrays. Through much of its (sometimes overzealous) build-up, toxicogenomics has found a natural niche as a bioinformatics and/or p...

journal_title：Pharmacogenomics

authors： Wills Q

更新日期：2007-08-01 00:00:00

abstract：AIM:Based on previous pharmacogenetic findings, we investigated the possible association between SULT4A1-1 haplotype and antipsychotic treatment response. MATERIALS & METHODS:Using Mixed Model Repeated Measures, we tested the relationship between SULT4A1-1 status (+carrier, -noncarrier) and clinical improvement (in Po...

journal_title：Pharmacogenomics

authors： Wang D,Li Q,Favis R,Jadwin A,Chung H,Fu DJ,Savitz A,Gopal S,Cohen N

更新日期：2014-01-01 00:00:00

abstract：AIMS:To study the frequency distribution of cytochrome P450 (CYP) functional genetic variants in five Eurasian populations from the territory of Siberia in Russia. MATERIALS & METHODS:Unrelated healthy Tuvinians, Buryats, Altaians, Yakuts and Russians (n = 87-88) were genotyped for CYP2C9*2, CYP2C9*3, CYP2C19*2, CYP2C...

journal_title：Pharmacogenomics

authors： Makeeva O,Stepanov V,Puzyrev V,Goldstein DB,Grossman I

更新日期：2008-07-01 00:00:00

abstract：:Cancers of the colon are commonly treated with fluoropyrimidines, which often cause severe toxicities in patients with certain variants in DPYD. Y186C (rs115232898) and a variant in the 3' untranslated region (rs12132152) are uncommon alleles previously observed in African-Americans. An African-American female underwe...

journal_title：Pharmacogenomics

authors： Sissung TM,Cordes L,Peer CJ,Gandhy S,Redman J,Strauss J,Figg WD

更新日期：2021-01-01 00:00:00

abstract：OBJECTIVES:Three exonic single nucleotide polymorphisms (SNPs) in the cytochrome P450 2B6 (CYP2B6) gene, 516G>T, 785A>G and 1459C>T, have been described to be associated with functional changes in the CYP2B6 catalytic activity or protein expression. They are therefore of potential clinical importance for drug efficacy ...

journal_title：Pharmacogenomics

authors： Rohrbacher M,Kirchhof A,Geisslinger G,Lötsch J

更新日期：2006-10-01 00:00:00

abstract：:Psoriasis vulgaris is one of the most prevalent T cell-mediated inflammatory diseases in humans. It is multifactorial in origin and shows polygenic inheritance. Systemic immunosuppressive therapies play an important role in management of severe disease cases but are associated with variable response and toxicity. With...

journal_title：Pharmacogenomics

authors： Ameen M

更新日期：2003-05-01 00:00:00

abstract：:Biobanking became a necessity for translating genetic discoveries into clinical practice. Approaches to personalized medicine require a new model system for functional and pharmacogenomic studies of a variety of accumulating genetic variations, as well as new research environments such as biobankomics. Human lymphobla...

journal_title：Pharmacogenomics

authors： Nam HY,Shim SM,Han BG,Jeon JP

更新日期：2011-06-01 00:00:00

abstract：:Randomized controlled trials are the gold standard for determining the efficacy of therapeutic interventions. However, medical practice has not evolved around the concept of randomized trials, but around the idea of careful observations, (anecdotal) case studies and the evaluation of retrospective data. Interventions ...

journal_title：Pharmacogenomics

authors： Frueh FW

更新日期：2009-07-01 00:00:00

abstract：:The response to lipid-lowering drugs is modified by a number of factors like age, gender, concomitant disease and genetic determinants. Even within homogenous groups of patients, individual responses vary greatly. Until now, no clinical or biochemical parameter exists which predicts whether a subject will respond well...

journal_title：Pharmacogenomics

authors： Hoffmann MM,Winkelmann BR,Wieland H,März W

更新日期：2001-05-01 00:00:00

abstract：:In vitro human cell line models have been widely used for cancer pharmacogenomic studies to predict clinical response, to help generate pharmacogenomic hypothesis for further testing, and to help identify novel mechanisms associated with variation in drug response. Among cell line model systems, immortalized cell line...

journal_title：Pharmacogenomics

authors： Niu N,Wang L

更新日期：2015-01-01 00:00:00

abstract：AIM:To investigate the pharmacokinetics of voriconazole when administered to HIV-positive patients receiving treatment with atazanavir-containing therapies according to CYP2C19 genotype. MATERIALS & METHODS:We describe four HIV-positive patients with pulmonary aspergillosis treated with voriconazole and atazanavir-bas...

journal_title：Pharmacogenomics

authors： Calcagno A,Baietto L,Pagani N,Simiele M,Audagnotto S,D'Avolio A,De Rosa FG,Di Perri G,Bonora S

更新日期：2014-07-01 00:00:00